Lumvoa emerges as strong Tepezza rival—but SC Tepezza looms on the horizon on July 09, 2026 Amgen Approved IGF1R protein, human Lumvoa subcutaneous Tepezza Thyroid associated opthalmopathies United States Food and Drug Administration Viridian +
Viridian's Lumvoa Gains FDA Nod for Thyroid Eye Disease, Setting Up Clash With Amgen's Tepezza on July 05, 2026 Amgen Tepezza active chronic thyroid eye disease Lumvoa FDA NALF2 gene subcutaneous elegrobart Thrive THRIVE-2 trials Viridian +
Viridian Licenses Promising Eye Disease Candidates to Kissei for Japanese Market on July 31, 2025 Antibodies Biopharma Clinical Trials Dosage Forms Japan Kissei Partnership Thyroid associated opthalmopathies veligrotug Viridian VRDN-003 +